A Comparative Retrospective Study of Immunotherapy RANO Versus Standard RANO Criteria in Glioblastoma Patients Receiving Immune Checkpoint Inhibitor Therapy

Xin Chen, Mary Jane Lim-Fat, Lei Qin, Angie Li, Annie G. Bryant, Camden Bay, Lu Gao, Nityanand Miskin, Zaiyi Liu, J. Bryan Iorgulescu, Xiaoyin Xu, David A. Reardon, Geoffrey S. YoungFrontiers in Oncology 2021 · DOI

Abstract

Standard RANO and iRANO have high concordance for assessing progressive disease (PD) in patients within 6 months of immune checkpoint blockade (ICB) initiation. iRANO was beneficial in 6% (3/49) of cases later proven to be pseudoprogression (PsP), but delayed confirmation of PD by less than 3 months in 4% (2/49). PsP occurred in 12% of patients, starting at up to 7 months after initiation of ICB. Further study to define the utility of modified RANO compared with iRANO in ICB glioblastoma (GBM) patients is needed.

Introduction

Glioblastoma (GBM) is an aggressive brain cancer with poor outcomes, leading researchers to explore Immune Checkpoint Blockade (ICB) therapies. However, assessing treatment efficacy radiologically is a major challenge. Standard Response Assessment in Neuro-Oncology (RANO) criteria define progressive disease based on increased tumor size or new lesions. In immunotherapy, inflammation can mimic tumor growth on MRI—a phenomenon known as pseudoprogression (PsP). To prevent premature treatment termination, the iRANO criteria were introduced, requiring a three-month follow-up to confirm progression if worsening occurs early in treatment.

Serial MRI scans (Axial T1 with gadolinium and Axial T2 FLAIR) illustrating the radiological challenge of distinguishing tumor progression from treatment-induced inflammation over 17 weeks.

Methods

This retrospective study evaluated 49 GBM patients (7 newly diagnosed, 42 recurrent) treated with ICBs (e.g., nivolumab, pembrolizumab) at a single institution. Serial MRI scans were analyzed to quantify tumor burden using the sum of products of the two largest perpendicular diameters of enhancing lesions. Patient responses were graded using both RANO and iRANO criteria and categorized into three groups: concordant non-progressors (Group 1), discordant cases (Group 2), and concordant progressors (Group 3).

Key Results

The study found an 88% concordance rate between RANO and iRANO. iRANO successfully identified PsP in 6% (3/49) of patients, allowing them to continue therapy for an additional 42 to 82 days. However, iRANO delayed the diagnosis of true progression in 4% (2/49) of patients by 42 and 93 days. PsP was not limited to the early treatment phase, appearing as late as 7 months post-initiation.

Survival analysis demonstrated that Group 1 (concordant non-progressors) had a significantly longer median Overall Survival (OS) of 24.3 months compared to Group 3 (concordant progressors, 8.1 months). Median Progression-Free Survival (PFS) was slightly longer when assessed by iRANO (3.7 months) versus RANO (2.7 months), reflecting the built-in waiting period of the iRANO criteria.

Kaplan-Meier survival curves showing survival probability over time for concordant non-progressors (Group 1), discordant cases (Group 2), and concordant progressors (Group 3).

Discussion and Conclusion

While iRANO is a valuable tool for identifying pseudoprogression and preventing the premature cessation of potentially effective immunotherapy, it carries the risk of delaying the transition to salvage therapies when treatment is truly failing. The study's limitations include a small sample size and retrospective design. Future research should compare iRANO with "modified RANO" (mRANO) to further refine the balance between detecting PsP and confirming true progression in GBM patients receiving immunotherapy.

Summary updated

Abstract

Standard RANO and iRANO have high concordance for assessing PD in patients within 6 months of ICB initiation. iRANO was beneficial in 6% (3/49) cases later proven to be PsP, but delayed confirmation of PD by <3 months in 4% (2/49). PsP occurred in 12% of patients, starting at up to 7 months after initiation of ICB. Further study to define the utility of modified RANO compared with iRANO in ICB GBM patients is needed.
BibTeX
@inproceedings{chen2021comparative,
  author = {Xin Chen and Mary Jane Lim-Fat and Lei Qin and Angie Li and Annie G. Bryant and Camden Bay and Lu Gao and Nityanand Miskin and Zaiyi Liu and J. Bryan Iorgulescu and Xiaoyin Xu and David A. Reardon and Geoffrey S. Young},
  title = {{A Comparative Retrospective Study of Immunotherapy RANO Versus Standard RANO Criteria in Glioblastoma Patients Receiving Immune Checkpoint Inhibitor Therapy}},
  booktitle = {Frontiers in Oncology},
  year = {2021},
  doi = {10.3389/fonc.2021.679331},
}
Figure